Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2011

View Archived Issues

Preclinical and clinical data on migalastat made available

ViroPharma and Halozyme begin phase II trial of Cinryze with rHuPH20

Study identifies SNPs implicated in response to lithium therapy for bipolar disorder

BET subfamily inhibitor targets Myc-dependent malignancies

Inhibitor of P. aeruginosa type III secretion system shows promise in preclinical studies

Advanced Cancer Therapeutics and University of Louisville claim new cancer therapeutics

Fluorocoxib probe may allow earlier diagnosis of nonmelanoma skin cancer

Sanofi transfers Hyalgan rights back to Fidia Farmaceutici

Trius Therapeutics begins phase III tedizolid trials

Taisho sodium/glucose cotransporter 2 inhibitor shows promise in patients with type 2 diabetes

New fusion polypeptides disclosed

Aestus Therapeutics to develop in-licensed Prosidion product for new indication

Inhibitex begins dosing in phase II INX-189 study

Vaxin receives BARDA grant for anthrax vaccine

Bayer Schering Pharma prepares novel vasopressin receptor ligands

New angiotensin AT2 receptor antagonists/PPAR-gamma agonists synthesized by Kowa

Researchers at Almirall patent novel tyrosine-protein kinase inhibitors

Keryx Biopharmaceuticals completes enrollment in long-term Zerenex trial

OncoGenex expands inclusion criteria for SATURN study

Max-Planck-Gesellschaft and Sanofi partnership aims at restoring vision

FDA approves Prolia for new indications

Scripps Research Institute presents new fluorinated vinca alkaloids

Phase II Trimesta study reaches enrollment target

Sanofi Pasteur begins shipping Fluzone in U.S.

Takeda launches Liovel tablets in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...